Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

globenewswire

THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) — Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an…

More Press Releases

May 6, 2026

Defiance Launches AMPU: The First Daily 2X Long ETF for Amprius Technologies, Inc.

May 6, 2026

ThredUp Doubles Down on Resale-as-a-Service® (RaaS®); Appoints Strategic Advisory Board to Scale Universal Recommerce Layer

May 6, 2026

Industry Leaders Demonstrate Integrated Post-Quantum Security Solutions at OFC 2026

May 6, 2026

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

Defiance Launches AMPU: The First Daily 2X Long ETF for Amprius Technologies, Inc.

ThredUp Doubles Down on Resale-as-a-Service® (RaaS®); Appoints Strategic Advisory Board to Scale Universal Recommerce Layer

Industry Leaders Demonstrate Integrated Post-Quantum Security Solutions at OFC 2026

VEON’s Kyivstar Authorized to Resell Starlink for Businesses & Enterprises in Ukraine